Giants67

@giants1967.bsky.social

16 hours ago

Stocks Under $0.10: ITRM, PLYX, AMLM, BFRG, QNCX, ADMQ March Madness Watch Getting your Trinity Audio player ready... A group of sub-$0.10 and low-priced small-cap stocks is drawing increased attention as investors rotate into high-beta, low-float names across biotechnology,...

The Street Reports Sub-$0.10
thestreetreports.com/stocks-under...
#AMLM #BFRG #ADMQ #ITRM #PLYX #QNCX

Stock Master

@stockmaster70.bsky.social

17 hours ago

📢 Stocks Trending NOW: #RZLV #ELAB #XOM #BFRG #ITRM #AA #SYY #FRMI #VRDN #SGML

@techblog98.bsky.social

21 hours ago

SPARK Matrix?: IT Risk Management, Q1 2025 QKS Group's IT Risk Management market research includes a comprehensive analysis of the global marke...

IT Risk Management Solutions: What Businesses Need to Know in 2026

qksgroup.com/market-resea...

#ITRiskManagement #RiskManagement #Cybersecurity #GRC #ITRM #GovernanceRiskCompliance #RiskManagementSolutions #CyberRisk #ITSecurity

StockTitan

@stocktitan.net

3 days ago

Iterum Therapeutics Announces Filing of Winding Up Petition Iterum Therapeutics (Nasdaq: ITRM) filed a petition in the High Court in Ireland to wind up the company and was placed in provisional liquidation on March 27, 2026.A court hearing is set for April 13, 2026; Joint Provisional Liquidators from Teneo were appointed to oversee winding down and potential dissolution.

#ITRM Iterum Therapeutics Announces Filing of Winding Up Petition

www.stocktitan.net/news/ITRM/iterum-therape...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

3 weeks ago

Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Shares of Ouster Inc (NASDAQ: OUST ) rose sharply in pre-market trading after the company reported better-tha...

#PreMarket #Movers #$NEAR #BATL #BURU #CRDO #Gainers #HROW […]

[Original post on benzinga.com]

StockTitan

@stocktitan.net

3 months ago

Iterum Therapeutics Provides Business Update Iterum Therapeutics (Nasdaq: ITRM) provided a business update highlighting expanded market access for ORLYNVAH™ and regulatory engagement with the FDA.Key points: a new commercial contract tied to a major PBM adds coverage opportunities for more than 24 million lives starting early 2026; a second signed rebate agreement with a top-three Medicare Part D PBM positions ORLYNVAH™ for formulary inclusion covering more than 10 million lives as early as Q1 2026; the company requested an FDA meeting about a step-down therapy claim and the FDA set a January 24, 2026 goal date to provide written responses.

#ITRM Iterum Therapeutics Provides Business Update

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

3 months ago

Iterum Therapeutics Provides Business Update Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum” or “we”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital

#ITRM Iterum Therapeutics Provides Business Update

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

3 months ago

Iterum Therapeutics Provides Business Update Iterum Therapeutics (Nasdaq: ITRM) provided a business update on Dec 5, 2025 highlighting commercial access, distribution, and IP developments for ORLYNVAH™.Key items: nearly 25% of U.S. insured lives now have coverage for ORLYNVAH™, with more than 60 million insured lives reachable via varied plan designs; a signed rebate agreement with a top‑three Medicare Part D PBM positions ORLYNVAH™ for formulary inclusion as early as Q1 2026; ORLYNVAH™ is stocked at McKesson and Cencora to support physician procurement; and the European Patent Office signaled intent to grant a patent covering a sulopenem etzadroxil/probenecid bilayer tablet with projected expiry in December 2039.

#ITRM Iterum Therapeutics Provides Business Update

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

4 months ago

#ITRM Iterum Therapeutics Provides Business Update

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

4 months ago

Iterum Therapeutics Reports Third Quarter 2025 Financial Results Iterum Therapeutics (Nasdaq: ITRM) reported Q3 2025 results after commercially launching ORLYNVAH in the United States in August 2025 for uncomplicated urinary tract infections.Key financials: cash and cash equivalents $11.0M at Sept 30, 2025; Iterum said cash plus $2.6M ATM proceeds through Nov 13, 2025, fund operations into Q2 2026. Q3 product revenue was $0.4M. Q3 net loss was $9.0M and non-GAAP net loss was $7.3M. Management expects 2026 net product sales of ORLYNVAH to range $5M–$15M, depending on uptake and payer coverage.Other items: granted patents in China (expires Mar 2041) and Mexico (expires Dec 2039), and a conference call was scheduled for Nov 14, 2025 at 8:30 a.m. ET.

#ITRM Iterum Therapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

6 months ago

New Antibiotic ORLYNVAH Launches in US: Iterum Therapeutics Targets Multi-Drug Resistant Infections Iterum's ORLYNVAH antibiotic launches in 7 US states with EVERSANA partnership. Company secures patents in China and Mexico, receives FDA 510(k) clearance for susceptibility testing, extends runway into 2026.

#ITRM Iterum Therapeutics Provides Business Update

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

7 months ago

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. Iterum Therapeutics (Nasdaq: ITRM) has launched ORLYNVAH™ (sulopenem etzadroxil and probenecid), marking a significant milestone as the first oral penem antibiotic available in the U.S. The FDA-approved treatment targets uncomplicated urinary tract infections (uUTIs) in adult women, specifically those caused by specific bacteria with limited treatment alternatives.The launch addresses a critical medical need, as 57% of initial UTI infections show resistance to at least one antibiotic class, and 13% are resistant to three or more antibiotics. ORLYNVAH™ represents the first new branded product for uUTI treatment in over 25 years. To enhance accessibility, Iterum is offering a copay savings program allowing eligible patients to obtain ORLYNVAH™ for as little as $25.

#ITRM Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

www.stocktitan.net/news/ITRM/iterum-therape...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

ITRM Reports Results | The Motley Fool

#ITRM #845f5064-3156-4741-9266-20e1c40c7a35 #data-news

Origin | Interest | Match

StockTitan

@stocktitan.net

7 months ago

Iterum Therapeutics Reports Second Quarter 2025 Financial Results Iterum Therapeutics (Nasdaq: ITRM) reported Q2 2025 financial results and announced the upcoming launch of ORLYNVAH™, the first branded antibiotic for uncomplicated urinary tract infections (uUTIs) in over 25 years. The company reported a net loss of $6.5 million for Q2 2025, compared to $5.0 million in Q2 2024.Key developments include a partnership with EVERSANA for U.S. commercialization, a manufacturing agreement with ACS Dobfar S.p.A, and the appointment of Christine Coyne as Chief Commercial Officer. The company's cash position of $13.0 million, plus $2.2 million raised through ATM offering, is expected to fund operations into 2026.ORLYNVAH™, the only FDA-approved oral penem antibiotic in the U.S., targets resistant Gram-negative bacteria, including ESBL-producing Enterobacterales. The company also secured patent protection in Canada until 2039 and had its REASSURE Phase 3 trial results published in NEJM Evidence.

#ITRM Iterum Therapeutics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

9 months ago

Iterum Strengthens Launch Strategy: 30-Year Pharma Veteran Christine Coyne to Lead ORLYNVAH Commercialization Former Innoviva CCO brings 30 years of anti-infective expertise to accelerate ORLYNVAH's US launch. Learn how this strategic hire shapes Iterum's growth trajectory.

#ITRM Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

www.stocktitan.net/news/ITRM/iterum-names-c...

StockTitan

@stocktitan.net

9 months ago

New Antibiotic Shows Promise Against Drug-Resistant UTIs: NEJM Evidence Reveals 9.2% Multi-Resistance Rate Clinical trial reveals effectiveness against resistant UTI pathogens. ORLYNVAH launch expected next quarter. See full resistance data and commercial timeline.

#ITRM Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

9 months ago

Breakthrough UTI Drug ORLYNVAH Set for Q4 2025 Launch: First Oral Penem Antibiotic in US History Iterum partners with EVERSANA to launch groundbreaking UTI treatment ORLYNVAH. First-ever oral penem antibiotic targets Q4 2025 US debut. See launch strategy.

#ITRM Iterum Therapeutics Announces Partnership for Commercialization Services

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

10 months ago

Iterum Therapeutics Announces Extension of Term of Promissory Note Iterum Therapeutics (NASDAQ: ITRM) announced that Pfizer has agreed to extend the payment deadline for a $20.0 million regulatory milestone payment from October 2026 to October 25, 2029. The milestone payment is associated with the FDA approval of ORLYNVAH™, which was received on October 25, 2024. Under the amended terms, the annual interest rate will increase from 8% to 10% (compounded daily) starting October 26, 2026.The extension allows Iterum to strategically invest capital raised or earned from ORLYNVAH™ sales into expanding into new territories and focusing on high-prescribing geographies. The amended agreement includes restrictions on ITIL's ability to incur senior debt or create liens on its assets without Pfizer's consent.

#ITRM Iterum Therapeutics Announces Extension of Term of Promissory Note

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

10 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results Iterum Therapeutics (NASDAQ: ITRM) reported its Q1 2025 financial results and provided updates on ORLYNVAH™, its FDA-approved treatment for uncomplicated urinary tract infections (uUTIs). The company is preparing for a potential Q4 2025 launch while pursuing strategic transaction opportunities. Key financial highlights include: - Cash position of $12.7 million as of March 31, 2025 - Raised additional $5 million through a registered direct offering and $1 million via ATM program - Extended cash runway into 2026 - Q1 2025 net loss of $4.9 million, improved from $7.1 million in Q1 2024 - Research and development expenses decreased to $0.6 million from $4.0 million year-over-year The company plans to launch ORLYNVAH™ either through a commercial partner or independently with a targeted sales force, focusing on addressing the growing antimicrobial resistance issue in uUTI treatment.

#ITRM Iterum Therapeutics Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

11 months ago

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today

#ITRM Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

11 months ago

Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients Latest research presented at ECCMID 2025 unveils crucial findings on age-related antibiotic resistance patterns in urinary tract infections. Full analysis inside.

#ITRM Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

1 year ago

Iterum's Landmark UTI Drug ORLYNVAH Powers Financial Turnaround in Q4 Report ITRM reports 35% lower losses following ORLYNVAH FDA approval. Cash runway into H2 2025, R&D costs down 74% as commercialization phase begins.

#ITRM Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/ITRM/iterum-therape...

@itrm.bsky.social

1 year ago

🦃🌟 This Thanksgiving, we reflect on our gratitude for our amazing clients. Thank you for being a part of our journey. Warm wishes from IT Resource Marketing! #Grateful #MarketingExperts #ITResourceMarketing #ITRM #thanksgiving

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #ITRM ) Iterum Therapeutics Regains Full Nasdaq Compliance

#StockMarket #News

StockTitan

@stocktitan.net

1 year ago

#ITRM Iterum Therapeutics Regains Full Nasdaq Compliance

www.stocktitan.net/news/ITRM/iterum-therape...

StockTitan

@stocktitan.net

1 year ago

#ITRM Iterum Therapeutics Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/ITRM/iterum-therape...

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #ITRM ) Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH(TM) (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #ITRM ) Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

#StockMarket #News